Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Long-Term Investments: 2020-2024

Historic Long-Term Investments for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $39.8 million.

  • Caribou Biosciences' Long-Term Investments fell 77.38% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year decrease of 77.38%. This contributed to the annual value of $39.8 million for FY2024, which is 8.55% down from last year.
  • Per Caribou Biosciences' latest filing, its Long-Term Investments stood at $39.8 million for FY2024, which was down 8.55% from $43.6 million recorded in FY2023.
  • In the past 5 years, Caribou Biosciences' Long-Term Investments registered a high of $69.4 million during FY2022, and its lowest value of $7.6 million during FY2020.
  • Over the past 3 years, Caribou Biosciences' median Long-Term Investments value was $43.6 million (recorded in 2023), while the average stood at $50.9 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first spiked by 394.05% in 2021, then slumped by 37.18% in 2023.
  • Over the past 5 years, Caribou Biosciences' Long-Term Investments (Yearly) stood at $7.6 million in 2020, then soared by 394.05% to $37.7 million in 2021, then soared by 84.13% to $69.4 million in 2022, then tumbled by 37.18% to $43.6 million in 2023, then fell by 8.55% to $39.8 million in 2024.